AI-Driven Computational Design of Peptide-Based WWP1 Inhibitors as Promising Therapeutic Agents Against Breast Cancer, Including Triple-Negative Subtype
WI23-B is highlighted as a promising lead peptide with potent WWP1 inhibitory activity and synergistic antiproliferative effects when combined with PI3K inhibitors, and has the potential to reshape therapeutic strategies for BC and TNBC by enabling more effective and less toxic treatment regimens.